Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAOUL DEVIN NELSON

Allopathic & Osteopathic Physicians Pediatrics Pediatric Nephrology

NPI
1972682540
CMS profile
1188095
Location
SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$211.48

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $211.48 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $211.48 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAOUL DEVIN NELSON

NPI 1972682540 · CMS profile ID 1188095

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Nephrology

SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972682540?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAOUL DEVIN NELSON, NPI 1972682540, CMS profile ID 1188095. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972682540?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RAOUL DEVIN NELSON, NPI 1972682540, CMS profile ID 1188095. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972682540?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RAOUL DEVIN NELSON, NPI 1972682540, CMS profile ID 1188095, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1972682540?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $211.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $71.5010/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087124650 CMS
Novartis Pharmaceuticals Corporation $139.9804/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087124642 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $3.82 1
PY2022 $30.43 2
PY2023 $69.74 1
PY2024 $211.48 2
PY2025 $1,850.79 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $251,671.53 36
PY2024 Principal investigator $323,155.10 45
PY2023 Principal investigator $143,206.45 25
PY2022 Principal investigator $34,814.75 7
PY2021 Principal investigator $86,188.09 9
PY2020 Principal investigator $21,071.22 4
PY2019 Principal investigator $25,818.87 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $11,646.00 12/22/2025 Non-covered Recipient Entity
University Of Utah
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <1 No dispute reported 06/30/2026 1225415002
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,185.00 12/17/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A single-arm, multicenter, Phase III study to assess efficacy, pharmacokinetics, safety and tolerability of iptacopan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN) No dispute reported 06/30/2026 1190309578
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,037.00 11/25/2025 Non-covered Recipient Entity
University Of Utah
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <1 No dispute reported 06/30/2026 1225415398
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,800.00 11/17/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
A single-arm, multicenter, Phase III study to assess efficacy, pharmacokinetics, safety and tolerability of iptacopan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN) No dispute reported 06/30/2026 1190296456
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,185.33 11/10/2025 Non-covered Recipient Entity
PRIM CHILDRENS HOSPITAL INV PHARMACY
A single-arm, multicenter, Phase III study to assess efficacy, pharmacokinetics, safety and tolerability of iptacopan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN) No dispute reported 06/30/2026 1190311965
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,037.49 10/28/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH HUNTSMAN CANCER INSTITUTE
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) No dispute reported 06/30/2026 1190300357
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $10,970.00 10/23/2025 Non-covered Recipient Entity
University Of Utah
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <1 No dispute reported 06/30/2026 1225413974
Principal investigator 1 Hoffmann-La Roche Limited $1,441.00 10/16/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558483
Principal investigator 1 Hoffmann-La Roche Limited $1,500.00 10/16/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558491
Principal investigator 1 Hoffmann-La Roche Limited $4,530.00 10/16/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558495
Principal investigator 1 Hoffmann-La Roche Limited $4,863.00 10/16/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558500
Principal investigator 1 Hoffmann-La Roche Limited $8,046.00 10/02/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558487
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,037.00 09/30/2025 Non-covered Recipient Entity
University Of Utah
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <1 No dispute reported 06/30/2026 1225414756
Principal investigator 1 Hoffmann-La Roche Limited $885.00 09/04/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558478
Principal investigator 1 ABBVIE INC. $2,184.00 08/26/2025 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1202423814
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,920.00 06/23/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1241841271
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,239.00 06/23/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1241841273
Principal investigator 1 AKEBIA THERAPEUTICS INC $10,722.00 06/23/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease No dispute reported 06/30/2026 1241841275
Principal investigator 1 Hoffmann-La Roche Limited $411.00 06/17/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558440
Principal investigator 1 Hoffmann-La Roche Limited $1,900.00 06/17/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558445
Principal investigator 1 Hoffmann-La Roche Limited $500.00 06/17/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558449
Principal investigator 1 Hoffmann-La Roche Limited $2,225.00 06/17/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558453
Principal investigator 1 Hoffmann-La Roche Limited $500.00 06/17/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558474
Principal investigator 1 Hoffmann-La Roche Limited $2,725.00 06/05/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558470
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,332.00 05/30/2025 Non-covered Recipient Entity
University Of Utah
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <1 No dispute reported 06/30/2026 1225412800
Principal investigator 1 Amgen Inc. $710.71 05/27/2025 Covered Recipient Teaching Hospital
U OF UTAH NEUROPSYCHIATRIC INSTITUTE
Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis No dispute reported 06/30/2026 1246638282
Principal investigator 1 Hoffmann-La Roche Limited $411.00 05/20/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558457
Principal investigator 1 Hoffmann-La Roche Limited $500.00 05/20/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558461
Principal investigator 1 Hoffmann-La Roche Limited $1,900.00 05/20/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome No dispute reported 06/30/2026 1211558466
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $25,682.00 04/30/2025 Non-covered Recipient Entity
NAPRTCS
A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 18 YEARS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) No dispute reported 06/30/2026 1225335849
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $23,350.00 04/30/2025 Non-covered Recipient Entity
NAPRTCS
A PHASE 3B MULTICENTER OPEN-LABEL TRIAL OF THE SAFETY, TOLERABILITY, AND EFFICACY OF TOLVAPTAN IN INFANTS AND CHILDREN 28 DAYS TO LESS THAN 12 WEEKS OF AGE WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) No dispute reported 06/30/2026 1225335851
Principal investigator 1 ABBVIE INC. $887.25 03/24/2025 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
M11-617 - A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1202423494
Principal investigator 1 ABBVIE INC. $750.75 02/26/2025 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
M11-617 - A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) No dispute reported 06/30/2026 1202423406
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,800.00 02/20/2025 Non-covered Recipient Entity
University Of Utah
BAY 948862, A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 mo No dispute reported 06/30/2026 1225403577
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $27,059.00 02/20/2025 Non-covered Recipient Entity
University Of Utah
BAY 948862, A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 mo No dispute reported 06/30/2026 1225405412
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $10,800.00 02/20/2025 Non-covered Recipient Entity
University Of Utah
BAY 948862, A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 mo No dispute reported 06/30/2026 1225406836